Enterprise-Wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2017

Enterprise-wide Disclosures [Abstract]

Schedule of Geographic Area Information

Total revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the customer, licensee or grantor (in thousands):

	Year Ended December 31,
Geographic Area	2017		2016		2015
United States	$	1,651	$	4,497	$	5,976
Foreign (1)		1,807		1,426		1,060
Total revenues	$	3,458	$	5,923	$	7,036

(1) Foreign revenues are primarily earned in Israel.

The composition of BioTime’s long-lived assets, consisting of property, plant and equipment, net, between those in the United States and in foreign countries, as of December 31, 2017 and 2016, is set forth below (in thousands):

	2017 (1)		2016 (2)
Domestic	$	2,746	$	3,418
Foreign		2,787		2,111
Total	$	5,533	$	5,529

(1)	Reflects the effect of the OncoCyte Deconsolidation.
(2)	Reflects the effect of the Asterias Deconsolidation.

Schedule of Sources of Revenues

The following table shows our major sources of revenues, as a percentage of total revenues, that were recognized during the years ended December 31, 2017, 2016, and 2015:

	Year Ended December 31,
Sources of Revenues	2017		2016		2015
CIRM grant income (1)		-%		38.0%		42.7%
NIH grant income (2)		5.0%		-%		6.5%
IIA (formerly OCS) grant income (Cell Cure, Israel)		43.2%		24.0%		14.4%
Subscriptions, advertising, licensing and other (various customers) (3)		49.4%		35.0%		29.4%
Other		2.4%		3.0%		7.0%

(1)	Reflects income from grants to Asterias from the California Institute for Regenerative Medicine (CIRM) prior to the Asterias Deconsolidation.
(2)	For 2017, reflects income from grants to BioTime from the National Institutes of Health (NIH). For 2015, reflects income from grants to ReCyte Therapeutics from the NIH.
(3)	For each of 2017 and 2016, one individual customer represents greater than 5% of total revenues. For 2015, no individual customer greater than 5% of total revenues.